The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics.
COVID-19
Cross-sectoral
Epidemiology
Longitudinal study
Population-based
Prospective national cohort
SARS-CoV-2
Journal
European journal of epidemiology
ISSN: 1573-7284
Titre abrégé: Eur J Epidemiol
Pays: Netherlands
ID NLM: 8508062
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
21
01
2022
accepted:
22
06
2022
pubmed:
30
7
2022
medline:
14
9
2022
entrez:
29
7
2022
Statut:
ppublish
Résumé
The German government initiated the Network University Medicine (NUM) in early 2020 to improve national research activities on the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic. To this end, 36 German Academic Medical Centers started to collaborate on 13 projects, with the largest being the National Pandemic Cohort Network (NAPKON). The NAPKON's goal is creating the most comprehensive Coronavirus Disease 2019 (COVID-19) cohort in Germany. Within NAPKON, adult and pediatric patients are observed in three complementary cohort platforms (Cross-Sectoral, High-Resolution and Population-Based) from the initial infection until up to three years of follow-up. Study procedures comprise comprehensive clinical and imaging diagnostics, quality-of-life assessment, patient-reported outcomes and biosampling. The three cohort platforms build on four infrastructure core units (Interaction, Biosampling, Epidemiology, and Integration) and collaborations with NUM projects. Key components of the data capture, regulatory, and data privacy are based on the German Centre for Cardiovascular Research. By April 01, 2022, 34 university and 40 non-university hospitals have enrolled 5298 patients with local data quality reviews performed on 4727 (89%). 47% were female, the median age was 52 (IQR 36-62-) and 50 pediatric cases were included. 44% of patients were hospitalized, 15% admitted to an intensive care unit, and 12% of patients deceased while enrolled. 8845 visits with biosampling in 4349 patients were conducted by April 03, 2022. In this overview article, we summarize NAPKON's design, relevant milestones including first study population characteristics, and outline the potential of NAPKON for German and international research activities.Trial registration https://clinicaltrials.gov/ct2/show/NCT04768998 . https://clinicaltrials.gov/ct2/show/NCT04747366 . https://clinicaltrials.gov/ct2/show/NCT04679584.
Identifiants
pubmed: 35904671
doi: 10.1007/s10654-022-00896-z
pii: 10.1007/s10654-022-00896-z
pmc: PMC9336157
doi:
Banques de données
ClinicalTrials.gov
['NCT04679584', 'NCT04747366', 'NCT04768998']
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
849-870Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : FKZ: 01KX2021
Informations de copyright
© 2022. The Author(s).
Références
Front Neurosci. 2020 Dec 07;14:611194
pubmed: 33364921
Ann Intern Med. 2021 Jan;174(1):125-127
pubmed: 32687717
Int J Infect Dis. 2020 Oct;99:266-268
pubmed: 32771632
Eur Respir J. 2020 Jun 4;55(6):
pubmed: 32269086
BMJ Open. 2020 Jun 21;10(6):e039097
pubmed: 32565483
Front Neurosci. 2013 Jun 10;7:95
pubmed: 23772204
Infection. 2021 Aug;49(4):703-714
pubmed: 33890243
Biopreserv Biobank. 2020 Dec;18(6):483-491
pubmed: 32871085
J Cardiovasc Magn Reson. 2020 Sep 3;22(1):61
pubmed: 32878639
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Eur Stroke J. 2019 Jun;4(2):181-188
pubmed: 31259266
BMJ. 2021 Apr 7;373:n826
pubmed: 33827854
Crit Care Med. 2021 Feb 1;49(2):209-214
pubmed: 33105150
PLoS Med. 2020 Sep 22;17(9):e1003379
pubmed: 32960880
JAMA Netw Open. 2021 Jul 1;4(7):e2116901
pubmed: 34255046
Infection. 2021 Dec;49(6):1277-1287
pubmed: 34642875
J Epidemiol Glob Health. 2021 Jun;11(2):137-139
pubmed: 33876599
N Engl J Med. 2021 Aug 19;385(8):678-681
pubmed: 33979506
Infection. 2020 Aug;48(4):619-626
pubmed: 32535877
J Am Med Inform Assoc. 2021 Mar 1;28(3):427-443
pubmed: 32805036
CMAJ Open. 2021 Mar 8;9(1):E181-E188
pubmed: 33688026
BMC Infect Dis. 2020 Oct 19;20(1):777
pubmed: 33076848
Rev Invest Clin. 2020;72(3):151-158
pubmed: 32584330
BMC Med Inform Decis Mak. 2020 Dec 21;20(1):341
pubmed: 33349259
N Engl J Med. 2021 May 13;384(19):1866-1868
pubmed: 33761203
N Engl J Med. 2021 Aug 12;385(7):577-579
pubmed: 34192429
Biomed J. 2020 Aug;43(4):314-317
pubmed: 32563697
Infection. 2021 Feb;49(1):63-73
pubmed: 33001409
Clin Chem. 2003 Apr;49(4):624-33
pubmed: 12651816
J Infect Public Health. 2020 Nov;13(11):1601-1610
pubmed: 32778421
Nature. 2021 May;593(7858):182-185
pubmed: 33981057